Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CN-105 in healthy adults
NCT02670824Phase 1Completed
- Sponsor
- AegisCN LLC
- Start
- Dec 2015
- Primary completion
- May 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in intracerebral hemorrhage (ICH) comparing CN-105 with Placebo (2 arms). Primary endpoint: Suspected Adverse Reactions at 1 week. Started Dec 2015; status: completed.
02
Drugs
CN-105
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT02670824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670824.